Sugi Predict

Sugi Predict / Compounds / SCHEMBL171078

SCHEMBL171078

SCHEMBL171078

COC(=O)CP(=O)(OCC(F)(F)F)OCC(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.37
▸ TSHR P16473 3/20 0.34
▸ HTT P42858 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ MGAM O43451 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ SI P14410 1/20 0.32
▸ MGAM2 Q2M2H8 1/20 0.32
▸ TET2 Q6N021 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ RECQL P46063 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18704548 0.93 TSHR (0.36) POLBTSHRHSD17B10CYP2C9NPC1
SCHEMBL12330742 0.93 POLB (0.35) POLBTSHRHTTHSD17B10MGAM
SCHEMBL9558843 0.81 TSHR (0.32) TSHRHTTHSD17B10MGAMGAA
SCHEMBL1135973 0.81 SMN1; SMN2 (0.41) POLBTSHRHTTHSD17B10MGAM
SCHEMBL15951726 0.81 TSHR (0.41) TSHRHTTHSD17B10MGAMGAA
SCHEMBL1792626 0.80 HTT (0.37) HTT
SCHEMBL2721085 0.80 LMNA (0.33) TSHRHTT
SCHEMBL2994665 0.80 HTT (0.34) HTTSMN1; SMN2
SCHEMBL14567463 0.79 ALDH1A1 (0.35) HTTCYP1A2CYP2C9
SCHEMBL2987492 0.79 HTT (0.32) TSHRHTTHSD17B10CYP2C9NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462124-B1 MESOIONIC PESTICIDES DU PONT (US) 2014-01-08 — — EP claimed
US-8062816-B2 Phosphonate hole blocking layer photoconductors XEROX CORPORATION (US) 2011-11-22 — — US claimed
US-8053151-B2 Phosphonate containing photoconductors XEROX CORPORATION (US) 2011-11-08 — — US claimed
US-20090297967-A1 PHOSPHONATE HOLE BLOCKING LAYER PHOTOCONDUCTORS XEROX CORPORATION (US) 2009-12-03 — — US claimed
US-20080096905-A1 Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives GLAXO GROUP LIMITED (GB) 2008-04-24 — — US claimed
EP-1865959-A2 PROCESS FOR PREPARING PYRIDOÝ2,3-D¨PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDOÝ4,5-D¨PYRIMIDIN-2(1H)-ONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2007-12-19 — — EP claimed
US-20060258687-A1 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives GLAXO GROUP LIMITED (GB) 2006-11-16 — — US claimed
WO-2006104917-A2 PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2006-10-05 — — WO claimed
EP-3684773-B1 THAILANSTATIN ANALOGS PH PHARMA CO LTD (KR) 2026-04-29 — — EP disclosed
US-20260001903-A1 ASCAROSIDE DERIVATIVES AND METHODS OF USE CALIFORNIA INSTITUTE OF TECHNOLOGY 2026-01-01 — — US disclosed
US-12473323-B2 Ascaroside derivatives and methods of use CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2025-11-18 — — US disclosed
EP-4640688-A1 AVERMECTIN DERIVATIVE Meiji Seika Pharma Co., Ltd. (JP) 2025-10-29 — — EP disclosed
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer ARTIOS PHARMA LIMITED (GB) 2025-07-15 — — US disclosed
WO-2025104443-A1 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2025-05-22 — — WO disclosed
EP-0402646-A1 Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1990-12-19 — — EP disclosed
US-4963547-A HYPOTENSIVE AGENTS SMITHKLINE BEECHAM CORPORATION (US) 1990-10-16 — — US disclosed
US-4959360-A α-adrenergic receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1990-09-25 — — US disclosed
WO-1989012050-A1 alpha-ADRENERGIC RECEPTOR ANTAGONISTS SMITHKLINE BECKMAN CORPORATION (US) 1989-12-14 — — WO disclosed
WO-1989012054-A1 alpha-ADRENERGIC RECEPTOR ANTAGONISTS SMITHKLINE BECKMAN CORPORATION (US) 1989-12-14 — — WO disclosed
EP-0342541-A2 Retroviral protease inhibitors ABBOTT LABORATORIES (US) 1989-11-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258687-A1 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives CBR3, CBR1, CYP2S1 POLB 844/4885TSHR 249/4885HTT 4137/4885
US-20080096905-A1 Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives CYP2S1, CYP2F1, CBR3 POLB 1140/4885TSHR 470/4885HTT 3897/4885
US-12473323-B2 Ascaroside derivatives and methods of use TLR4, TLR7, MYD88 POLB 4336/4885TSHR 4782/4885HTT 4601/4885
US-20260001903-A1 ASCAROSIDE DERIVATIVES AND METHODS OF USE HSD3B2, HSD3B1, NLRP3 POLB 4558/4885TSHR 3655/4885HTT 1625/4885
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer SDHA, DPYD, TP53 POLB 459/4885TSHR 3750/4885HTT 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.